The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Background and aims. The inflammatory bowel diseases (IBD), Crohn's disease (CD) and
ulcerative colitis (UC), are chronic relapsing disorders of unknown aetiology. The aim of this …

Background Knowledge of the cost of illness of inflammatory bowel disease (IBD) is
essential for health policy makers worldwide. Aim To assess the cost of illness of IBD from …

Background Globally, the incidence rates of inflammatory bowel disease (IBD) are
increasing; however, data from high‐incidence areas are conflicting. Previous studies in …

Introduction Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the
colon, characterized by relapsing and remitting symptoms. Although traditionally viewed as …

Direct health care costs of illness reflect the costs of medically necessary services and
treatments paid for by public and private payers, including hospital-based care, outpatient …

Background With the increasing use of anti-TNF therapy in inflammatory bowel disease
(IBD), a shift of costs has been observed with medication costs replacing hospitalization and …

Canada has among the highest rates of IBD in the world, and the number of people living
with these disorders is growing rapidly. This has placed a high burden on the health care …

Objective: Inflammatory bowel disease [IBD] entails a high economic burden to society. We
aimed to estimate the current and future impact of the introduction of biosimilars for …

Abstract Background and Aims Inflammatory bowel disease [IBD] places an economic strain
on health systems due to expensive pharmaceutical therapy, risk of hospitalisation and …